EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Recombinant Human Interleukin-2 Corrects NK Cell Phenotype and Functional Activity in Patients with Post-COVID Syndrome

Andrei A Savchenko iD, Igor V Kudryavtsev, Dmitry V Isakov, Ivan S Sadowski, Vasily D Belenyuk iD, Alexandr G Borisov iD

Pharmaceuticals · 03.04.2023 · 16 (4) · 537

DOI: 10.3390/ph16040537 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 03.04.2023. Verfasst von Andrei A Savchenko und 5 weiteren Autor:innen. Beteiligte Einrichtung: Federal Research Center "Krasnoyarsk Science Center" of the Siberian Branch of the Russian Academy of Sciences, Scientific Research Institute of Medi…. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Federal Research Center "Krasnoyarsk Science Center" of the Siberian Branch of the Russian Academy of Sciences, Scientific Research Institute of Medical Proble…, Institute of Experimental Medicine within the framework of State Task FGWG-2022-0005, “Research Institute of Medical Problems of the North”.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Post-COVID syndrome develops in 10–20% of people who have recovered from COVID-19 and it is characterized by impaired function of the nervous, cardiovascular, and immune systems. Previously, it was found that patients who recovered from infection with the SARS-CoV-2 virus had a decrease in the number and functional activity of NK cells. The aim of the study was to assess the effectiveness of recombinant human IL-2 (rhIL-2) administered to correct NK cell phenotype and functional activity in patients with post-COVID syndrome. Patients were examined after 3 months for acute COVID-19 of varying severity. The phenotype of the peripheral blood NK cells was studied by flow cytometry. It was found that disturbances in the cell subset composition in patients with post-COVID syndrome were characterized by low levels of mature (p = 0.001) and cytotoxic NK cells (p = 0.013), with increased release of immature NK cells (p = 0.023). Functional deficiency of NK cells in post-COVID syndrome was characterized by lowered cytotoxic activity due to the decreased count of CD57+ (p = 0.001) and CD8+ (p < 0.001) NK cells. In the treatment of patients with post-COVID syndrome with recombinant IL-2, peripheral blood NK cell count and functional potential were restored. In general, the effectiveness of using rhIL-2 in treatment of post-COVID syndrome has been proven in patients with low levels of NK cells.

Schlagwörter

Stichwörter der Autor:innen

NK cellfunctional activityimmunorehabilitationpost-COVID syndromerecombinant human interleukin-2subset composition

Autor:innen und Institutionen

  • Federal Research Center "Krasnoyarsk Science Center" of the Siberian Branch of the Russian Academy of Sciences, Scientific Research Institute of Medical Problems of the North, 660022 Krasnoyarsk, Russia.
  • Institute of Experimental Medicine, 197376 St. Petersburg, Russia.
  • School of Biomedicine, Far Eastern Federal University, 690922 Vladivostok, Russia.
  • Institute of Experimental Medicine, Pavlov First St. Petersburg State Medical University of the Russian Federation Ministry of Healthcare, 197022 St. Petersburg, Russia.

ORCID-Profile: Andrei A Savchenko, Vasily D Belenyuk, Alexandr G Borisov

Förderung

  • Federal Research Center "Krasnoyarsk Science Center" of the Siberian Branch of the Russian Academy of Sciences, Scientific Research Institute of Medical Proble…
  • Institute of Experimental Medicine within the framework of State Task FGWG-2022-0005
  • “Research Institute of Medical Problems of the North”
  • State Assignment of Institute of Experimental Medicine

Zitieren

APA

Savchenko, A. A., Kudryavtsev, I. V., Isakov, D. V., Sadowski, I. S., Belenyuk, V. D., & Borisov, A. G. (2023). Recombinant Human Interleukin-2 Corrects NK Cell Phenotype and Functional Activity in Patients with Post-COVID Syndrome. Pharmaceuticals, 16(4), 537. https://doi.org/10.3390/ph16040537

Vancouver

Savchenko AA, Kudryavtsev IV, Isakov DV, Sadowski IS, Belenyuk VD, Borisov AG. Recombinant Human Interleukin-2 Corrects NK Cell Phenotype and Functional Activity in Patients with Post-COVID Syndrome. Pharmaceuticals. 2023;16(4):537. doi:10.3390/ph16040537

BibTeX
@article{Savchenko2023,
  author = {Savchenko, Andrei A and Kudryavtsev, Igor V and Isakov, Dmitry V and Sadowski, Ivan S and Belenyuk, Vasily D and Borisov, Alexandr G},
  title = {Recombinant Human Interleukin-2 Corrects NK Cell Phenotype and Functional Activity in Patients with Post-COVID Syndrome},
  journal = {Pharmaceuticals},
  year = {2023},
  volume = {16},
  number = {4},
  pages = {537},
  doi = {10.3390/ph16040537}
}
Kostenlos starten →